Innovative Minds France's Most Impactful Healthcare Leaders.pdf

Innova ve
Minds:
France’s
MostImpac ul
Healthcare
Leads
Phippe
Vwade
Architect of Advancements
in Drug Discovery
Phippe Vwade
Presidt and CEO
Alzprote
Inves ng in Tomorrow
The Rise of Biomedicine
in France
Innova ng for Impact
France's Push for
Emerging Infec ous
Disease Research
MAY
ISSUE 01
2024

Shaping the Future of France’s Healthcare
System
rance has long been revered for its
Fcontributions to the world of medicine
and healthcare. From future-driven
surgical techniques to groundbreaking
pharmaceutical discoveries, the nation’s rich
legacy is interwoven with countless
innovations that have transformed patient
care globally.
In this special edition, we celebrate the
Innovative Minds: France’s Most
Impactful Healthcare Leaders. The
individuals featured in these pages represent
the best and brightest minds dedicated to
advancing patient care, pioneering new
treatments, and improving overall health
outcomes. Their relentless commitment to
their craft has yielded innovative discoveries,
novel approaches, and a profound impact on
countless lives.
As you delve into these inspiring stories,
you’ll gain insights into the minds that are
shaping the future of healthcare. From
renowned leaders pushing the boundaries of
what’s possible to researchers tirelessly
seeking cures for the world’s most challenging
diseases, each proﬁle oﬀers a glimpse into the
passion, dedication, and ingenuity that fuel
their work.
We hope that this edition will not only inspire
you but also shed light on the invaluable
contributions these leaders have made to the
healthcare community. Their pursuit of
excellence serves as a reminder of the
transformative power of innovation and the
immense potential it holds for improving
human health and well-being.
Join us in celebrating these remarkable
individuals and their extraordinary
achievements as we explore the innovative
minds driving France’s healthcare sector to
new heights.
Indulge in an insightful read ahead!
Visionary
Medical Minds
-Natalie May
NatalieMay

24
32
Articles
Contents
Innovating for Impact
France’s Push for Emerging
Infectious Disease Research
Investing in Tomorrow
The Rise of Biomedicine
in France
Profiles
18 Marie Pirotais
Driving Ultimate
Progress
28 Nicolas Martelin
Pioneering Healthcare
Transformation through
Innovative Fusion

08
Philippe Verwaerde
in Drug Discovery
Cover Story

Copyright © 2024 Insights Success Media and Technology Pvt. Ltd., All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any form or
by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights success.
Reprint rights remain solely with Insights Success Media and Technology Pvt. Ltd. Euro Health Leaders is powered by Insights Success Media and Technology Pvt. Ltd.
sales@eurohealthleaders.com
Contact Us:
Insights Success Media Tech LLC
555 Metro Place North, Suite 100,
Dublin, OH 43017, United States
Phone - +1614-602-4132
Email: info@eurohealthleaders.com
For Subscription: www.eurohealthleaders.com
Insights Success Media and Technology Pvt. Ltd.
Survey No.133/134, Brand Square, Oﬃce No. 512,
Kunjir Chowk, Pimple Saudagar, Pune,
Maharashtra 411027.
Phone - India: 7410033802, 8956487823
We are also available on :
Editor-in-Chief
Thanh Truong
Managing Editor
Pearl Shaw
Executive Editor
Natalie May
Visualiser
David King
Art & Design Head
Samuel Martinez
Co-designer
Paul Belin
Art & Picture Editor
Grace Brown
Business Development
Manager
Emily Jones
Marketing Manager
Bill Thompson
Business Development
Executives
Anna Smith, Jack Miller
Sales Executives
Mike, Carl, Sandra
Technical Head
Jacob Smile
Assistant Technical Head
Joseph Taylor
Technical Consultants
David, Robert
Digital Marketing
Manager
Alina Sege
Assistant Digital
Marketing Manager
Daniel Jones
SME-SMO Executive
Gemson
Research Analyst
Eric Smith
Circulation Manager
James Carter
L E A D E R S
EUR Health
MAY, 2024
Follow us on : www.facebook.com/eurohealthleaders/ https://twitter.com/eurohealthleaders

Brief
Featuring
Person
Company
Frederic Desdouits is a versatile professional
blending science, finance, and business acumen in
the global pharma & biotech sector.
Marie Pirotais, a visionary leader with 25 years of R&D
experience, drives innovation at Biosency, pioneering
non-invasive health monitoring technologies with
strategic acumen and market expertise.
Caroline Tranvouez is a seasoned professional with
extensive experience in the pharmaceutical and
cosmetics industry.
Treefrog Therapeutics
treefrog.fr
Frederic Desdouits
CEO
Caroline Tranvouez
Medical Officer
Marie Pirotais
Co-founder and CEO
Farmea (Groupe Fareva)
fareva.com
Biosency
biosency.com
Nicolas Martelin is a forward-thinking leader who is
revolutionizing healthcare through the strategic
integration of finance and healthcare.
Philippe's journey spans pharmacology,
entrepreneurship, and biopharmaceutical
leadership, driving innovation in neurodegenerative
disease treatments, particularly Alzheimer's and
tauopathies.
Prostperia
prostperia.com
Nicolas Martelin
President & Co-founder
Philippe Verwaerde
President and CEO
Alzprotect
alzprotect.com
INNOVATIVE MINDS: FRANCE'S MOST
IMPACTFUL HEALTHCARE LEADERS

Phippe Vwade
Presidt and CEO
Alzprote

Phippe
Vwade
in Drug Discovery
Cov
Story
Alzprotect is ready to signiﬁcantly
contribute to advancements in
trea ng neurodegenera ve diseases
in the coming years by focusing on
the development and reﬁnement of
targeted therapies like AZP2006.

edicated healthcare leaders are driven by passion
Dand commitment to contributing meaningfully to
the well-being of their communities. Among these
leaders is Philippe Verwaerde, an experienced professional
who has positively impacted healthcare. With over 35 years
of international involvement in academic research, the
pharmaceutical industry, and biotech companies, Philippe is
known as an innovator and community servant.
Philippe’s journey began with achievements in
pharmacology within the pharmaceutical and biotech
sectors, where he led research teams as a laboratory
manager and department director. Subsequently, he
ventured into entrepreneurship, co-founding Vivactis in
Belgium and iNovacia in Sweden—both players in
pharmaceutical discovery and development services.
Currently serving as the President and CEO of ,
Alzprotect
a biopharmaceutical company in Lille, France, Philippe
directs his expertise and passion toward developing
innovative treatments for neurodegenerative diseases,
including Alzheimer’s disease and tauopathies.
Alzprotect’s mission to create groundbreaking therapeutic
solutions addresses a crucial gap in healthcare, as there are
currently no available treatments to slow down or halt
neurodegenerative diseases, affecting millions worldwide.
Philippe’s leadership at Alzprotect shows dedication to a
major global health issue.
This exclusive feature explores Philippe's inspiring journey,
uncovering the qualities that have positioned him as one of
France's impactful healthcare leaders.
From Microscopes to Metabolic Diseases
Philippe, hailing from a working-class family in Northern
France, worked hard to become a dedicated scientist. His
dream of becoming a researcher began when he received
his first microscope at age 11. Philippe recalls, “This gift
solidified my determination to pursue a career in biology.”
At the age of 14, Philippe achieved his first ‘Philips
Scientific Prize for Young Scientists,’ marking the
beginning of his scientific journey. This accomplishment
was followed by two more recognitions, including the
European Young Scientist Award in 1981, leading to his
first publication. In 1982, he won the “National Biology
I love the idea of making
a difference in people’s
lives. It’s incredible to
think that our work
could help someone with
a serious illness.
Alzprotect

Competition” and successfully completed his baccalaureate.
These achievements led to his doctorate in Biology nine
years later, a moment that made his parents proud.
To broaden his horizons and deepen his expertise, Philippe
embarked on a journey to the United States, spending two
and a half years at Rutgers University (NJ) for further
training. By the end of 1993, he returned to Europe to
contribute to biotech and pharmaceuticals. Philippe reflects
on his international career, recalling, “My journey led me to
Italy, Belgium, and Sweden, where I led research teams as a
laboratory head and department director before venturing
into entrepreneurship.”
Throughout his career, Philippe has overseen various
projects in the research and clinical development of
innovative drugs, with a keen focus on metabolic diseases,
microbiology, and neuroscience.
Alzprotect—Advancing Neurodegenerative Solutions
Alzprotect, headquartered in Lille, France, stands as a
notable biopharmaceutical company, working on
neurodegeneration and tauopathies. Focused on developing
effective treatments, the company’s mission encompasses
the entire journey from drug discovery to proving efficacy
in clinical trials for neurodegenerative disorders like
Alzheimer’s disease (AD) and Progressive Supranuclear
Palsy (PSP).
Philippe underscores the company’s key expertise in
tauopathies. He explains, “Our focus lies in understanding
diseases where neuronal degeneration is intricately linked
to the abnormal accumulation of hyperphosphorylated Tau
proteins and neuroinflammation.” This specialized
knowledge has led to a groundbreaking discovery in the
form of AZP2006, a promising drug candidate

demonstrating potent effects in controlling
neurodegeneration.
AZP2006’s mechanism of action is comprehensive,
targeting all known markers of neurodegeneration. Philippe
elaborates, “This innovative drug addresses critical factors
such as Amyloid beta peptide, Tau protein,
Neuroinflammation, and Oxidative stress.”
Breakthrough in Neurodegenerative Disease Treatment
AZP2006 emerges as a promising drug, carefully designed
to target specific processes within brain cells. Its
mechanism involves elevating levels of the crucial protein
PGRN, integral to the brain’s waste disposal system, known
as lysosomes. Philippe emphasizes, “AZP2006 also shows
potential in protecting brain cells, promoting their survival
and connection, and reducing harmful inflammation.”
The drug’s impact extends to addressing tau pathology, a
pivotal feature in various neurodegenerative diseases.
AZP2006 achieves this by mitigating harmful protein
modifications associated with tau. Philippe further
elaborates, “AZP2006 shows a significant positive effect on
synaptogenesis, evidenced in neuron cultures and mouse
models that fully recovered from severe
neurodegeneration.”
The promising outcomes extend to animal studies, where
AZP2006 demonstrated a notable improvement in learning
and memory. Philippe notes, “This improvement suggests
promising outcomes for human patients, especially for
Alzheimer’s treatment.” The potential for patients to regain
learning abilities and recognize loved ones presents a
hopeful prospect, marking a major step in the quest to treat
Alzheimer’s disease.
However, Philippe underlines the importance of future
research to validate these findings, noting that confirming
these results could be a major advance. in the treatment
landscape for Alzheimer’s disease.
Strategic Leadership
Philippe leads a multidisciplinary team, focusing on the
scientific and operational aspects. His leadership is pivotal,
with a focus on steering the team through the complexities
of neurodegeneration research. Philippe’s responsibilities
include a range of important tasks, ranging from resource
and budget management to ensuring the seamless alignment
of scientific objectives with operational efficiency.
One of Philippe’s key roles involves thorough resource and
budget management, a task essential for supporting project
progression while maintaining financial health. Meeting
strict regulatory standards stands as a cornerstone of his
responsibilities, reflecting a commitment to patient safety
and the upholding of research integrity. Recognizing the
importance of risk management, Philippe balances project
stability with the uncertainties of scientific work.
Engaging with stakeholders and collaborating closely with
the Chief Medical Officer, Philippe oversees clinical trials,
placing high importance on safety and data integrity. His
leadership style promotes a culture of innovation in
neurodegeneration research, with a strong focus on data
analysis and reporting.
In reflecting on his multifaceted role, Philippe remarks,
“Promoting innovation in neurodegeneration research and
ensuring effective data analysis and reporting are also vital.
Overall, my role integrates strategic leadership with
scientific and operational management.”
Balancing Passion and Practicality
Philippe derives great satisfaction from the multifaceted
aspects of his work, focused on improving health and
Promo ng innova on in
neurodegenera on research and
ensuring effec ve data analysis and
repor ng are also vital. Overall, my
role integrates strategic leadership
with scien fic and opera onal
management.
Innova ve Minds: France's Most Impac ul Healthcare Leaders

developing medicines. He states, “First and foremost, I find
immense joy in the prospect of positively impacting
people's lives. It's truly incredible to hope our efforts can
help those with serious illnesses.”
The excitement of exploration holds special significance in
Philippe’s professional journey. Science, like a complex
puzzle, captivates him as he and his team systematically
piece together its components. Philippe shares, “Each
discovery is an important milestone. – not just for us, but
for the fields of science and medicine.”
Beyond the confines of the laboratory, Philippe takes
pleasure in promoting the growth of the company. The
entrepreneurial journey, reminiscent of growing a small
idea into a successful enterprise., presents challenges that
Philippe approaches with determination. “It's undeniably
challenging, but witnessing the company's success is
incredibly satisfying,” he observes.
Acknowledging the complexities inherent in his role, such
as solving intricate problems and ensuring compliance with
safety protocols and regulations, Philippe underscores,
“Overcoming challenges makes our successes more
rewarding.” The intersection of science and business
introduces an additional layer to Philippe’s narrative.
Recognizing the mutual relationship, he emphasizes that the
company’s financial success not only benefits the team but
is also essential for continuing important research and the
development of new medicines.
Philippe adeptly navigates the delicate equilibrium between
his passion for science and the pragmatic considerations of
managing a business. This equilibrium is paramount in
ensuring the continuity of their mission—leveraging the
power of science to create a meaningful impact in people's
lives.
Navigating the Challenges
Leading drug discovery for neurodegenerative diseases
requires specific skills. Philippe emphasizes the need for
deep understanding of both chemistry and biology,
highlighting the importance of staying updated with the
latest research developments.
He also highlights the significance of problem-solving in
this demanding role, stating, “Problem-solving is key, as
challenges like unexpected reactions or ambiguous test
AZP2006 shows a significant
posi ve effect on synaptogenesis,
evidenced in neuron cultures
and mouse models that fully
recovered from severe
neurodegenera on.
results are common.” Effective communication is a
necessary skill, allowing clear communication of complex
scientific information to the team, partners, and investors.
Collaboration is deemed vital in this endeavor, requiring
Philippe to work closely with a diverse team of scientists,
encouraging unified efforts towards common goals. The
overall essence of the role involves the combination of
scientific expertise, strategic thinking, problem-solving,
clear communication, and teamwork.
Advancing Innovative Treatments for
Neurodegenerative Diseases
At Alzprotect, the team tackles the development of drug
candidates for conditions like Alzheimer’s and tauopathies
with a unique focus. Their goal extends beyond merely
slowing down or halting the progression of diseases; they
aspire to restore neuron connections and enhance brain
function. This precise targeting sets Alzprotect apart in the
field of neurodegenerative disease research.
Philippe, emphasizing the distinctive approach, notes, “Our
approach is grounded in rigorous scientific research and a
deep understanding of the molecular mechanisms
underlying neurodegeneration such as lysosome
dysfunction.” This scientific foundation highlights the
commitment to a comprehensive understanding of the
intricate processes involved in neurodegenerative
conditions.

The success achieved in the Phase 2a trials for Progressive Supranuclear
Palsy (PSP) stands as evidence to Alzprotect’s dedication to effective and
innovative treatments. In a landscape where such advancements are urgently
needed, Alzprotect’s progress in clinical trials signal a promising contribution
to the evolving field of neurodegenerative disease therapeutics.
Balancing Mission and Progress
As the leader of a biotech company committed to addressing
neurodegenerative diseases, Philippe emphasizes the importance of
effectively navigating fundraising and business development. Describing his
approach, Philippe highlights, “My approach highlighting our mission to
fight diseases. like Alzheimer’s, which affects millions and lacks sufficient
treatments. I make sure potential investors and partners grasp the significant
impact of our research on healthcare and patients.”
In Philippe’s strategic approach, effective
communication takes center stage. He aims
to communicate complex concepts clearly
and engagingly. This entails highlighting
breakthroughs and providing updates on
clinical trial progress to instill trust and
generate interest among investors. Beyond
the confines of the boardroom, Philippe
actively forges strong relationships through
networking with industry leaders,
scientists, and investors, recognizing the
symbiotic relationship between scientific
and financial progress.
Acknowledging the inherent risks and
expenses associated with drug discovery,
especially in challenging areas such as
Alzheimer’s, Philippe emphasizes the
importance of careful planning. He notes,
“Given the risky and expensive nature of
drug discovery, especially in areas like
Alzheimer’s, I always prepare solid plans
for funding usage, risk management, and
future steps to reassure investors of our
potential.”
Furthermore, Philippe maintains a constant
focus on long-term goals, understanding
that success in biotech and
neurodegenerative diseases is a journey
that unfolds over years.
Charting the Future
In the landscape of healthcare’s future,
particularly within drug discovery and
neurodegenerative disease research, a
major shift towards personalized medicine
is on the horizon. Philippe underscores this
trajectory, stating, “Tailoring treatments
like AZP2006 to individual genetic profiles
will enhance efficacy and minimize side
effects.” Anticipated advancements in
biomarkers are poised to significantly
improve early detection and intervention in
neurodegenerative diseases, potentially
altering the course of these conditions.
The integration of artificial intelligence
(AI) and machine learning is set to play a

A Visionary
Approach to
Drug Discovery
pivotal role, significantly accelerating drug discovery and
development processes. Philippe envisions an evolution in
treatment approaches, potentially leaning towards
combination therapies that address diseases from multiple
angles to enhance outcomes.
This era of healthcare promises groundbreaking
advancements, marking a shift towards more personalized
and effective solutions in neurodegeneration. Philippe
affirms, “Alzprotect is ready to significantly contribute to
advancements in treating neurodegenerative diseases in the
coming years by focusing on the development and
refinement of targeted therapies like AZP2006.” The
company’s strategic focus revolves around leveraging the
promising results from Phase 2a trials for Progressive
Supranuclear Palsy (PSP) to further explore and understand
the efficacy of their treatments across a spectrum of
neurodegenerative disorders, including Alzheimer’s and
Parkinson’s diseases.
Insights for Future Leaders in Drug Discovery
As an experienced leader in drug discovery and
biopharmaceuticals, Philippe shares valuable advice for
aspiring professionals looking to make their mark in the
field. His guidance centers around developing scientific
curiosity, business intelligence, and resilience. Philippe
emphasizes, “Stay up to date with the latest scientific
advancements and technological innovations, as these are
crucial for breakthroughs in drug discovery.”
Networking and collaboration Networking and collaboration
are key to success, urging professionals to build robust
relationships with peers, mentors, and industry leaders.
Philippe advocates for embracing interdisciplinary learning,
encouraging a holistic understanding of regulatory
landscapes and market dynamics.
Most importantly, Philippe concludes, “Be prepared for
setbacks and challenges; perseverance and adaptability are
vital in this rapidly evolving field where success often
comes after numerous trials and learning from failures.”
Philippe employs a mul faceted approach to
maintain a holis c view and cul vate a
vision for future products. His strategies
revolve around con nuous research and
development, ensuring Alzprotect stays at
the forefront of scien fic advancements and
integrates these insights into its R&D
processes. This includes staying
well-informed about new discoveries in
neurodegenera ve diseases and emerging
technologies in biotech.
Collabora on plays a pivotal role as Philippe
ac vely seeks partnerships with leading
scien sts, clinicians, and experts in the field.
This collabora ve effort enables Alzprotect
to gain diverse perspec ves and deepen its
understanding of complex challenges.
Market trends and pa ent needs are also
cri cal considera ons in Philippe’s approach.
By keeping a close eye on these factors, he
ensures that Alzprotect’s product
development aligns with real-world
demands, making the company responsive
to the evolving healthcare landscape.
By encouraging the team to think crea vely
and explore novel approaches, Philippe
ensures that the company remains
adaptable and well-posi oned in the rapidly
evolving field of drug discovery.

It's not enough to just keep doing
what works; to stay ahead we
need to keep innovating.
- Ron Mobed
“

Marie Pirotais
Co-founder and CEO
Biosency

ith an intense earnestness for multidisciplinary
Wcollaboration where science, technology and
business intersect, Marie Pirotais has been
driving advancements in various sectors. She holds 25 years
of experience in Research and Development (R&D) and
innovation departments, where she has honed her expertise
in strategy, marketing and project management.
In 2015, Marie co-founded Cataris, a consulting company
focused on leveraging her diverse skill set to provide
strategic insights and solutions to clients. Building on this
foundation, she co-founded Biosency in 2017, a pioneering
company dedicated to developing a predictive medicine
solution based on specialized non-invasive physiological
monitoring and digital health solutions.
Marie’s extensive background in R&D, coupled with her
strategic acumen and marketing savvy, positions her as a
visionary leader in the field of digital health. Her ability to
bridge the gap between scientific advancements and market
needs has been instrumental in guiding Biosency towards
success in developing cutting-edge health monitoring
technologies.
As the Co-founder and CEO of Biosency, Marie continues
to drive innovation and spearhead initiatives that push the
boundaries of what’s possible in digital health. Her
dedication to integrating the latest technologies with a deep
understanding of user needs underscores Biosency’s
commitment to revolutionizing healthcare through
non-invasive monitoring solutions.
Let us explore Marie’s transformative journey at Biosency,
where innovation meets impact in the world of digital
health.
Path to Healthcare Innovation
One of the most transformative experiences that profoundly
shaped Marie’s leadership journey at Biosency was the
recognition of the sheer potency in diverse perspectives.
Co-founding Biosency alongside Yann Le Guillou, whose
distinct background and thought processes diverged from
her own, served as a stark revelation of the inherent
strength found in diversity. This insight significantly
influenced her approach to leadership within their team.
Understanding that diverse perspectives foster innovation
and resilience, she actively sought to preserve and
encourage this diversity within their organization. It wasn’t
solely about individual skills but rather the collaborative
intelligence that emerged when an array of unique
viewpoints converged. This personal revelation proved
instrumental in cultivating an inclusive and innovative
culture at Biosency, propelling their collective efforts for
personalized, predictive, and participative medicine to
unprecedented heights.
Marie positioned Biosency as a leader in healthcare
innovation and endeavored to meet their ambitious goals
through several key strategies:
• Substantial investment in talented R&D, medical,
regulatory, and staff, as well as in clinical studies, to
bring tangible medical proof to the market on their
state-of-the-art predictive medicine solution. This
highlighted their commitment to regulatory excellence,
achieving CE MDR Class IIa certification as well as
ANS certification (French Digital Health Agency) on
cybersecurity and interoperability.
Marie
Pirotais
Driving Ultimate Progress
May 2024 www.eurohealthleaders.com
19

• Prioritization of user experience through intuitive
design and implementation of robust data security
measures.
• Collaboration with state-of-the-art research
laboratories, manufacturers, healthcare professionals,
and patients’ associations to build long-term
partnerships.
• Maintenance of the highest quality standards to meet
the challenges of the healthcare sector.
They firmly believed that healthcare innovation, if not
integrated into a care pathway, would not be able to deliver
all its potential added value to the healthcare system.
AI-driven Solutions
Founded six and a half years ago, Biosency is a French
start-up that provides predictive medicine solutions for
patients suffering from chronic respiratory insufficiency.
From the beginning, the company has focused on chronic
obstructive pulmonary disease or COPD, an
under-diagnosed pathology and the third leading cause of
death globally. According to the WHO, over 400 million
people worldwide suffer from the disease. COPD is
characterized by inflammation and slow, generally
progressive obstruction of the bronchial tubes.
In 80% of cases, it is linked to smoking, while the
remaining 20% are caused by occupational diseases
involving dust or pollution. Biosency’s cutting-edge
technology harnesses the power of data analytics and real-
time monitoring to detect respiratory issues early. Their AI-
based predictive solutions improve patient care by enabling
healthcare professionals to act upstream and anticipate
deterioration in patient health to prevent hospitalization and
patient re-admission.
By continuously tracking vital signs and scoring patient
health status deterioration, Biosency empowers both
patients and healthcare providers with actionable insights,
fostering a proactive approach to respiratory care.
The company is dedicated to staying at the forefront of
predictive medicine. Biosency aims to enhance the quality
of life for patients and contribute to a more sustainable
healthcare ecosystem.
20

Rising to the Challenge
During the height of the first COVID-19 pandemic
lockdown in March 2020, Marie recounts the challenging
situation Biosency faced when their subcontractor,
responsible for manufacturing their cutting-edge Bora band
vital sign wristbands, suddenly halted production.
This unexpected disruption left them with a severely limited
supply, unable to meet the overwhelming demand from
hospitals and pulmonologists for their recently CE DM
Class IIa certified remote monitoring solution. This
certification was crucial in facilitating the safe return home
of patients requiring oxygen therapy.
Determined to overcome this obstacle, Marie and her team
tapped into their extensive local economic network.
Through their efforts, they successfully obtained prefectural
authorization to reopen the factory during the lockdown
period.
This bold and proactive move allowed Biosency to swiftly
resume production of their Bora band wristbands, meeting
the critical needs of hospitals and pulmonologists who
relied on their solution for ensuring the secure at-home
recovery of patients on oxygen therapy.
Advancing Respiratory Care
Biosency adopts a strategic approach to collaborations and
partnerships, aiming to amplify its impact and extend its
reach within the healthcare industry. Marie and her team
prioritize the establishment of alliances with key
stakeholders, including industry leaders, research
institutions, and healthcare organizations.
By actively engaging patient associations as partners,
Biosency ensures that its solutions are not only
technologically advanced but also deeply attuned to the
needs and experiences of those affected by respiratory
conditions. This inclusive approach underscores the
company’s commitment to developing patient-centric
solutions that address real-world challenges and enhance
the overall quality of care.
These collaborations serve as catalysts for innovation,
enabling Biosency to leverage collective expertise, share
knowledge, and remain at the forefront of advancements in
medical technology.
Commitment to Innovation and Patient-Centricity
Marie emphasizes that at Biosency, the team prioritizes
continuous innovation, agility, and patient-centricity,
ensuring that their solutions drive tangible improvements in
healthcare outcomes. Through strategic collaboration and
partnerships, they amplify their impact within the industry,
guided by data-driven decision-making, regulatory
excellence, and determined ethical standards. With a global
vision guiding their international expansion and a steadfast
dedication to nurturing talent, they empower a dynamic
poised for success.
Customer feedback holds utmost importance, serving as the
driving force behind their adaptability to the ever-changing
landscape of healthcare. Rooted in core values of ethics,
commitment, professionalism, and trust, these principles
foster a culture of unparalleled excellence, resilience, and
unwavering responsiveness. At Biosency, it’s their
dedicated team that embodies and champions these
fundamental values, propelling them towards continued
success.
Listening intently, demonstrating empathy, and valuing the
expertise of each individual are the cornerstones of their
commitment to shaping the future of respiratory care.
BIOSENCY AIMS TO
ENHANCE THE
QUALITY OF LIFE FOR
PATIENTS AND
CONTRIBUTE TO A
MORE SUSTAINABLE
HEALTHCARE
ECOSYSTEM.
21

Revolutionizing Healthcare with Predictive Medicine
With an aging population, a surge in chronic illnesses, the
aging of healthcare professionals, and the prevalence of
medical deserts, Marie emphasizes the urgent need for
transformation in our healthcare system. Biosency aims to
play a pivotal role in this transformation by providing the
technological foundation to advance predictive medicine
and telemonitoring. The integration of telemonitoring not
only empowers patients with confidence but also ensures
seamless continuity of care at home on a global scale.
Also, establishing a solid legal framework is paramount to
ensure patient safety, device efficacy, and interoperability.
Biosency is fully committed to aligning with this
framework, paving the way for reimbursement from the
French health insurance system. Additionally, the company
is diligently preparing for FDA clearance, with approval
anticipated by 2025.
The Roadmap to Success in Healthcare Leadership
Marie advises aspiring healthcare leaders that navigating
challenges and fostering innovation are paramount for
success. First and foremost, she suggests embracing
challenges as opportunities for growth and learning. The
healthcare landscape is dynamic, and adversity often serves
as a catalyst for innovation.
Therefore, it’s crucial to cultivate an environment that
encourages open communication and seamless
collaboration within your team and with external partners.
Marie emphasizes that it’s the fusion of diverse
perspectives that fuels and fortifies strength. She
recommends prioritizing patient-centric approaches,
developing unyielding resilience, and leading with a blend
of empathy and humility.
By embracing these principles, healthcare leaders can not
only navigate challenges effectively but also drive a culture
of continuous innovation in healthcare.
22

The Rise of
Biomedicine
in
France
24

The 19th and 20th centuries marked a profound shift
in the French medical landscape, as biomedicine –
an approach grounded in modern scientific
principles and biological understanding of the body –
supplanted long-held traditional healing practices. This rise
of biomedicine as the dominant medical framework was
facilitated by the legal system, which increasingly codified
it as the only legitimate means of treating patients.
Rise of a New Medical Paradigm
In a world where the frontiers of science and medicine are
rapidly evolving, France has emerged as a rising force in
the pioneering field of biomedicine. This multidisciplinary
domain, which integrates principles from biology,
engineering, and medicine, holds immense potential to
revolutionize healthcare through cutting-edge therapies and
technologies. With a rich history of scientific excellence
and a forward-thinking approach, France is investing
heavily in biomedical innovation to shape the medical
breakthroughs of tomorrow.
At the heart of France's biomedical boom is a strong
commitment from both the public and private sectors to
translate groundbreaking research into real-world
applications. The French government has made biomedical
R&D a strategic priority, allocating significant funding and
resources to support scientists, universities, and companies
operating in this space. This long-term vision recognizes
that the discoveries of today will pave the way for
transformative treatments and improved patient outcomes in
the years to come.
Cell and Gene Therapy Boom
One area where France is making notable strides is in the
development of advanced cell and gene therapies. These
innovative approaches, which harness the power of a
Inves ng in Tomorrow
25

patient's own cells or genetic material, have the potential to
address a wide range of diseases in entirely new ways.
Several French pharmaceutical giants and emerging biotech
companies are at the forefront of this revolution, investing
heavily in state-of-the-art production facilities and cutting-
edge research programs.
Regenerative Medicine Frontiers
Beyond cell and gene therapies, France is also a hub for
pioneering work in regenerative medicine – an exciting
field focused on regrowing or restoring damaged tissues and
organs. From revolutionary biomaterials that can induce
bone regeneration to stem cell therapies that could one day
restore function to injured organs, French researchers and
companies are pushing the boundaries of what's possible.
Another area of focus for France's biomedical ecosystem is
leveraging genomic data and precision medicine to tackle
rare diseases. Despite impacting millions worldwide, these
conditions have historically seen limited investment in
research and drug development due to small patient
populations. Through ambitious national initiatives, France
aims to establish itself as the first country to provide
universal access to genomic screening, analysis, and
personalized treatments tailored to each individual's unique
genetic profile.
The potential impact of these biomedical advances is
profound – offering hope to patients suffering from
devastating illnesses, reducing healthcare costs through
more effective treatments, and driving economic growth
through a thriving life sciences industry. Indeed, estimates
suggest that France's burgeoning biomedical sector could
create tens of thousands of high-quality jobs and generate
billions in revenue in the years ahead.
A Rich Research Ecosystem
Fueling this biomedical revolution is France's rich research
ecosystem and a steadily flowing talent pipeline. The nation
boasts world-class universities, institutes, and hospitals at
the cutting-edge of biomedical science – magnets for the
brightest minds from around the globe. These hubs of
innovation foster cross-disciplinary collaboration and
knowledge-sharing, accelerating the translation of
discoveries into marketable products and startups.
Facilitating Lab-to-Market
Recognizing the immense economic potential, both public
and private organizations in France are working tirelessly to
facilitate this critical path from lab to market. Government
initiatives aim to streamline regulatory processes, while
technology transfer companies assist in transforming
academic projects into commercially viable enterprises.
This holistic approach ensures that promising biomedical
innovations can rapidly advance from concept to reality.
At the same time, France's ascent as a biomedical leader is
attracting significant investment from international
pharmaceutical, biotech, and venture capital firms. These
companies are drawn by the nation's robust intellectual
property protections, business-friendly policies, and access
to a large pool of highly skilled talent. As global interest
and capital flows into the French biomedical sector, a
virtuous cycle of innovation and growth takes hold.
Conclusion
From the historic halls of the Pasteur Institute to the
advanced labs of modern biotech startups, France has a rich
scientific heritage that is now catalyzing the next generation
of biomedical breakthroughs. By investing today in
research, entrepreneurship, and the discoveries that will
Define the future of medicine, the nation is positioning
itself at the vanguard of a transformative field with the
power to enhance human health and longevity on an
unprecedented scale.
-Natalie May
26

The merging of finance and healthcare emerges as a
pathway to new possibilities, paving the way for
innovative solutions that enhance accessibility and
affordability. This fusion, though uncommon, ignites
transformative progress. Within this arena of opportunity,
Nicolas Martelin, President & Co-founder of Prostperia,
mirrors the strategic brilliance of visionary leaders.
Assuming leadership at Prostperia, Martelin is dedicated to
revolutionizing healthcare through pioneering solutions.
With a background in finance, he seamlessly integrates
diverse expertise to drive advancements. As a healthcare
leader, Martelin leverages visionary insight to enhance
accessibility and affordability, demonstrating steadfast
commitment to improving global healthcare outcomes.
So, let’s dive in to discover Nicolas Martelin's journey and
Prostperia's innovative approach to healthcare
transformation!
A Journey from Finance to Healthcare
Nicolas Martelin's journey from finance to healthcare
innovation began with a striking realization: while
considerable resources were allocated to financial market
research, cancer research was comparatively underfunded.
This prompted Martelin to question whether the advanced
technology and expertise employed in finance could be
leveraged to enhance cancer screening.
Martelin identified significant flaws in existing screening
tests, such as the PSA test for prostate cancer, which he
noted, "is wrong half of the time when positive." This led to
unnecessary stress and financial burdens for patients and
healthcare systems alike. Determined to address this issue,
Martelin collaborated with experts like biologist Brian
DeWitt and mathematician Benjamin Chen to develop a
superior solution.
Their collaborative effort resulted in the creation of the
PROSTia test, which was officially introduced with the
establishment of Prostperia in 2021. Martelin
acknowledged the crucial role played by urologist Pascal
Eschwege, whose expertise ensured that the test not only
met rigorous scientific standards but also provided tangible
benefits for patients and healthcare professionals.
Mission and Vision
Passionately speaking about Prostperia's core mission
Martelin highlights their steadfast dedication to patients and
the medical community. "From day one, it was clear to
Brian, Benjamin, and I that we were doing this for the
Nicolas
Martelin
Pioneering Healthcare Transforma on
through Innova ve Fusion
Martelin's profound reflec ons
highlight the deep connec on
between educa on and
leadership, showcasing how
his pedagogical background
serves as a founda on for
fostering innova on and
growth within Prostperia.
28

patients and the medical community," he
affirmed. Martelin outlined the company's
commitment to delivering patient-centric
cancer screening tools, leveraging
multiple patient-dependent data points to
enhance screening effectiveness.
He also emphasized Prostperia's
ambitious vision: a shift towards
prevention. "Our big vision is to go after a
too-often overlooked aspect: prevention,"
Martelin declared. He explained their goal
of transforming screening tests into
preventive measures, aiming not only to
save trillions of dollars annually but also
to extend millions of lives. Martelin
underscored the shared belief with
Benjamin and Brian that early detection
and disease prevention are paramount.
"Detecting disease is good, detecting it
early is better, and avoiding it is best," he
emphasized.
Integrating Cutting-Edge Science into
Prostperia's Development
Nicolas Martelin sheds light on how
Prostperia seamlessly integrates cutting-
edge scientific principles into their
products and services. He highlights their
comprehensive approach, leveraging
expertise across mathematics, biology,
economics, and cognitive science to drive
innovation in screening tests. Martelin
emphasizes their dynamic exploration of
new scientific concepts, always with a
clear focus on practical application and
impact.
Furthermore, he elaborates on their
rigorous evaluation process, wherein the
potential of new technologies is carefully
assessed based on their ability to advance
patient care. This meticulous approach
ensures that only innovations aligning
with the objective of enhancing patient
care are considered for integration.
Consequently, Prostperia maintains its
position at the forefront of healthcare
advancement.
Nicolas Martelin
President & Co-founder
Prostperia
29

Fostering Team Growth Through Educational
Experience
Reflecting on his dual roles as a lecturer and tutor, he shares
profound insights into how his educational background
influences his leadership approach at Prostperia. "When
you’re in a classroom or when you’re doing tutoring, you
have to find ways to get people interested in what you’re
saying," he begins. Martelin underscores the importance of
captivating an audience's attention, even when the subject
matter may seem dry, such as calculus. He elaborates, "You
have to give them a reason to learn."
Drawing from his experience, Martelin emphasizes the
fundamental role of inspiration and hope in education. "On
paper, I believe that the recipe for being a good lecturer is
simple," he explains. "You have to inspire your students so
that they want to listen to you, and you have to instill
hope." He passionately advocates for the transformative
power of hope, describing it as an "excellent catalyst for
progress, resilience, and eventually success."
Martelin relates Napoleon Bonaparte's assertion that "a
good leader is a dealer in hope" to his own journey,
suggesting that his experiences as an educator have shaped
his leadership style. "I guess being a lecturer and a tutor
taught me to be a leader," he reflects. Martelin highlights
the importance of sharing a compelling vision and
cultivating a sense of hope within the team. "If you share a
vision and can convey this idea of hope within your team,
you can really propel your team forward," he notes.
Martelin's profound reflections highlight the deep
connection between education and leadership, showcasing
how his pedagogical background serves as a foundation for
fostering innovation and growth within Prostperia.
Navigating Challenges as CEO
As President of Prostperia, Nicolas Martelin recalls a
significant challenge he faced and how he navigated
through it. He highlights the experience of developing the
second iteration of PROSTia, a screening tool designed to
detect prostate cancers. Martelin recalls the initial
excitement of creating a tool to identify as many cancers as
possible, only to receive unexpected feedback from
healthcare professionals. They expressed the need for a
screening tool that could differentiate between potential
cancers and highlight those with higher risks.
Acknowledging the initial disappointment, Martelin
emphasizes the pivotal moment when he reframed the
challenge as an opportunity for growth. Rather than seeing
it as a setback, he recognized it as a step towards refining
their approach and creating the best screening test possible.
Drawing inspiration from Mick Jagger's words, "you can’t
always get what you want but if you try, sometimes you get
what you need," Martelin highlights the importance of
perseverance and adaptability in the face of adversity.
From this experience, Martelin learns the value of resilience
and the importance of embracing feedback as a catalyst for
improvement. He recognizes that setbacks are not failures
but rather opportunities for growth and refinement. This
mindset shift empowers him and his team to continue their
pursuit of innovation, undeterred by challenges along the
way.
Balancing Local Healthcare Needs with International
Aspirations
Martelin stresses the global challenge of cancer and the
pressing need for better screening methods worldwide. He
recognizes the diverse healthcare systems across different
countries, making it challenging to design adaptable
products. Despite these obstacles, Martelin reaffirms
Prostperia's mission to provide accessible screening tests
globally, especially in underserved areas. He highlights the
concerning disparity in screening access and its impact on
cancer rates in certain regions.
www.eurohealthleaders.com
30

Currently, PROSTia is only available in France, but
Martelin emphasizes their commitment to global expansion.
Participation in the La Base accelerator program at HEC
Montreal aids in distribution, reflecting Prostperia's
dedication to overcoming barriers for global accessibility.
Defining Truly Impactful Leadership
Nicolas Martelin believes that truly impactful leaders
possess qualities such as hope, resilience, and the ability to
zoom out and see the bigger picture amidst challenges. He
emphasizes the importance of instilling hope, even in the
face of adversity, and the necessity of tapping into an "extra
gear" of mental toughness to keep motivation high within
the team.
Martelin draws inspiration from his love for the mountains,
which he views as an ideal setting for building mental
resilience. He sees his role as embodying these qualities in
his leadership style, consistently sharing hope and
maintaining a broader perspective to navigate obstacles
effectively.
He believes that impactful leadership is characterized by
hope, resilience, and the ability to rise above challenges. As
he states, "The keyword is 'Hope'."
Advice for Aspiring Healthcare Entrepreneurs
On asking about advice for aspiring healthcare
entrepreneurs, Nicolas Martelin offers pragmatic guidance.
He acknowledges the sector's challenges, such as stringent
regulations and lengthy timelines. Martelin advises tackling
these hurdles incrementally and highlights the importance
of perseverance and resilience.
He emphasizes the necessity of possessing a profound
passion for effecting change in healthcare and encourages
individuals to reflect on their commitment to their ideas.
Martelin suggests that a willingness to make significant
sacrifices indicates being on the right track.
To summarize, Martelin's advice focuses on perseverance,
passion, and self-reflection as essential for navigating the
complexities of the healthcare sector.
31

n the aftermath of the COVID-19 pandemic, a harsh reality
Ihas come into sharp focus – the world was ill-prepared to
respond to a crisis of such unprecedented scale and
virulence. As nations around the globe scrambled to contain the
spread of the deadly virus, healthcare systems were pushed to
their breaking points, economies faced disruption, and society
grinded to a halt.
The human toll of COVID-19 was staggering, with millions
losing their lives and exposing our vulnerability to emerging
infectious diseases in an interconnected world. No nation
escaped its wrath. From this calamity, a new urgency emerged to
fortify global defenses against future pandemics, with France
leading with an ambitious plan to spearhead the fight against
emerging pathogens.
A Multifaceted Approach
At the heart of France’s Emerging Infectious Disease Research
Plan is a multifaceted strategy that tackles the problem from
multiple angles. One key pillar is boosting fundamental virology
and immunology research to deepen the understanding of how
viral pathogens emerge, spread, and interact with the human
immune system.
State-of-the-art facilities and cutting-edge scientific equipment
will be established to accelerate these research endeavors,
creating an environment ripe for groundbreaking discoveries.
Funding will also be channeled towards attracting and nurturing
top scientific talent from around the world, ensuring that France
remains at the vanguard of these critical fields.
France’s
Push for Emerging
Infectious Disease
Research
Innova ng for Impact
32

33

Furthermore, the plan prioritizes the development of
innovative diagnostics, therapies, and vaccines against viral
threats through innovations in fields like genomics,
bioinformatics, and synthetic biology. By harnessing the
power of these cutting-edge technologies, researchers aim
to expedite the translation of scientific breakthroughs into
tangible clinical applications that can save lives during
future outbreaks.
Collaborative public-private partnerships between research
institutions and pharmaceutical companies will be fostered,
recognizing that synergistic efforts are crucial to accelerate
the development of effective countermeasures against
emerging pathogens.
Enhancing Surveillance and Prediction
Another cornerstone of France’s strategy is the bolstering of
real-time disease surveillance and predictive modeling
capabilities. By harnessing the power of big data analytics,
machine learning, and advanced computational techniques,
researchers aim to develop robust early warning systems
that can rapidly detect and forecast potential hotspots for
outbreaks before they spiral out of control.
This proactive approach to pandemic preparedness will be
fortified by investments in cutting-edge technologies like
high-throughput sequencing, which can rapidly identify and
characterize novel viral strains as they emerge. By staying
ahead of the curve, public health authorities can implement
targeted containment measures and mobilize resources
more effectively, potentially averting catastrophic
consequences.
A Shared Responsibility, a Global Impact
The unveiling of France’s Emerging Infectious Disease
Research Plan underscores the nation’s recognition that
strategic, long-term investments in scientific excellence are
crucial to fortifying global health security. As the world
grows increasingly interconnected through trade, travel, and
human migration, the threat of rapidly spreading pandemics
looms larger than ever before.
However, bolstering society’s defenses against the next
pandemic is not just a national imperative – it is a shared
responsibility among nations. By positioning itself at the
forefront of this battle, France is not only safeguarding its
own populace but also contributing to a broader
international effort to enhance pandemic preparedness
worldwide.
Through collaborative research initiatives, knowledge
sharing, and the dissemination of scientific breakthroughs,
the impacts of France’s strategic investments in this domain
are poised to ripple across borders, benefiting humanity as a
whole.
The Road Ahead
While the path ahead is arduous, France’s commitment to
"Innovating for Impact" in the field of emerging infectious
disease research is an alarm of hope in a world still reeling
from the devastation of COVID-19. By cultivating a culture
of scientific excellence, embracing futuristic technologies,
and promoting international collaboration, France is poised
to play a major role in mitigating the risks posed by the next
global health crisis.
As the world continues to struggle with the harsh lessons of
the COVID-19 pandemic, France’s bold vision serves as a
powerful reminder that investing in scientific prowess is not
just a matter of intellectual pursuit, but a matter of
safeguarding the very fabric of human civilization against
existential threats that transcend borders and boundaries.
In the face of adversity, humanity’s greatest defense has
always been the indomitable spirit of innovation and the
relentless pursuit of knowledge. France’s push for emerging
infectious disease research is a testament to this enduring
truth – a testament that will undoubtedly echo through the
ages as a shining example of society’s resilience in the face
of daunting challenges.
-Natalie May
34

Stay in touch.
Subscribe to Euro Health Leaders and
get the magazine in print, & digital on

Innovation
distinguishes between a
leaderand a
follower.

L E A D E R S
EUR Health

Innovative Minds France's Most Impactful Healthcare Leaders.pdf

Related slideshows

More Related Content

Similar to Innovative Minds France's Most Impactful Healthcare Leaders.pdf

Similar to Innovative Minds France's Most Impactful Healthcare Leaders.pdf (20)

More from eurohealthleaders

More from eurohealthleaders (9)

Recently uploaded

Recently uploaded (20)

Innovative Minds France's Most Impactful Healthcare Leaders.pdf